Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 8/20 | 0.49 |
| ▸ | CA2 | P00918 | 8/20 | 0.49 |
| ▸ | CA12 | O43570 | 6/20 | 0.49 |
| ▸ | CA9 | Q16790 | 6/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2032033 | 1.00 | MEN1 (0.69) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL4820814 | 0.95 | MEN1 (0.76) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL4820803 | 0.95 | MEN1 (0.76) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL2636479 | 0.88 | MEN1 (0.65) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL570909 | 0.88 | MEN1 (0.65) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL21056310 | 0.88 | MEN1 (0.65) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL19611471 | 0.87 | MEN1 (0.59) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL19611472 | 0.87 | MEN1 (0.59) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL1764468 | 0.87 | MEN1 (0.63) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL9327481 | 0.87 | MEN1 (0.73) | MEN1KMT2AGAATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243472-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-07-31 | — | — | US | claimed |
| CN-118256603-A | Modified enzymes | 牛津纳米孔科技公开有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-117264925-A | Modified enzymes | 牛津纳米孔科技公开有限公司 | 2023-12-22 | — | — | CN | claimed |
| CN-116601297-A | Modified helicase and application thereof | 北京齐碳科技有限公司 | 2023-08-15 | — | — | CN | claimed |
| US-20230212535-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-07-06 | — | — | US | claimed |
| EP-4198125-A2 | PIF1-LIKE HELICASE AND USE THEREOF | Qitan Technology Ltd., Beijing (CN) | 2023-06-21 | — | — | EP | claimed |
| US-11525125-B2 | Modified helicases | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2022-12-13 | — | — | US | claimed |
| EP-4063382-A9 | PIF1-LIKE HELICASE AND APPLICATION THEREOF | Qitan Technology Ltd., Beijing (CN) | 2022-11-16 | — | — | EP | claimed |
| EP-4063382-A1 | PIF1-LIKE HELICASE AND APPLICATION THEREOF | Qitan Technology Ltd., Beijing (CN) | 2022-09-28 | — | — | EP | claimed |
| US-20220290223-A1 | PIF1-LIKE HELICASE AND USE THEREOF | Qitan Technology Ltd. (CN) | 2022-09-15 | — | — | US | claimed |
| US-20210009971-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2021-01-14 | — | — | US | claimed |
| EP-3575410-A2 | MODIFIED ENZYMES | Oxford Nanopore Technologies Limited (GB) | 2019-12-04 | — | — | EP | claimed |
| US-20180037874-A9 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2018-02-08 | — | — | US | claimed |
| US-20160257942-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2016-09-08 | — | — | US | claimed |
| EP-3058088-A2 | MODIFIED ENZYMES | Oxford Nanopore Technologies Limited (GB) | 2016-08-24 | — | — | EP | claimed |
| US-20150191709-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2015-07-09 | — | — | US | claimed |
| EP-2875128-A1 | MODIFIED HELICASES | Oxford Nanopore Technologies Limited (GB) | 2015-05-27 | — | — | EP | claimed |
| WO-2015055981-A2 | MODIFIED ENZYMES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2015-04-23 | — | — | WO | claimed |
| WO-2014013260-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2014-01-23 | — | — | WO | claimed |
| EP-4702157-A1 | ACYL-TRNA SYNTHETASES | United Kingdom Research and Innovation (GB) | 2026-03-04 | — | — | EP | disclosed |
| EP-4702156-A1 | TRNA-BASED METHODS AND RELATED COMPOSITIONS | United Kingdom Research and Innovation (GB) | 2026-03-04 | — | — | EP | disclosed |
| US-20250243472-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-07-31 | — | — | US | disclosed |
| US-12258591-B2 | Modified helicases | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-03-25 | — | — | US | disclosed |
| CN-117264925-B | Modified enzymes | 牛津纳米孔科技公开有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-12252717-B2 | Modified helicases | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-03-18 | — | — | US | disclosed |
| US-20250027130-A1 | Nucleic Acid Synthesis and Sequencing Using Tethered Nucleoside Triphosphates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-23 | — | — | US | disclosed |
| US-20240417704-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-12-19 | — | — | US | disclosed |
| US-20240368568-A1 | MODIFIED PRP43 HELICASE AND USE THEREOF | QITAN TECHNOLOGY LTD., CHENGDU (CN) | 2024-11-07 | — | — | US | disclosed |
| WO-2024223922-A1 | ACYL-tRNA SYNTHETASES | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024223923-A1 | tRNA-BASED METHODS AND RELATED COMPOSITIONS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-10-31 | — | — | WO | disclosed |
| CN-114599666-B | Pif1-like helicase and application thereof | 北京齐碳科技有限公司 | 2024-08-06 | — | — | CN | disclosed |
| EP-4397970-A2 | MUTANT PORE | Oxford Nanopore Technologies PLC (GB) | 2024-07-10 | — | — | EP | disclosed |
| CN-118256603-A | Modified enzymes | 牛津纳米孔科技公开有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-111534504-B | Method of ligating one or more polynucleotide binding proteins to a target polynucleotide | 牛津纳米孔科技公开有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-4122949-B1 | MUTANT PORE | OXFORD NANOPORE TECH PLC (GB) | 2024-06-05 | — | — | EP | disclosed |
| CN-118086476-A | Modified enzymes | 牛津纳米孔科技公开有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117965707-A | Modified enzymes | 牛津纳米孔科技公开有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117947149-A | Modified enzymes | 牛津纳米孔科技公开有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117947148-A | Modified enzymes | 牛津纳米孔科技公开有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-11911488-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-02-27 | — | — | US | disclosed |
| US-11911488-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240026441-A1 | METHOD FOR ATTACHING ONE OR MORE POLYNUCLEOTIDE BINDING PROTEINS TO A TARGET POLYNUCLEOTIDE | Oxford Nanopre Technologies PLC (GB) | 2024-01-25 | — | — | US | disclosed |
| EP-4299746-A1 | MODIFIED PRP43 HELICASE AND USE THEREOF | Qitan Technology Ltd., Chengdu (CN) | 2024-01-03 | — | — | EP | disclosed |
| CN-117264925-A | Modified enzymes | 牛津纳米孔科技公开有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230374567-A1 | METHOD FOR MODIFYING A TEMPLATE DOUBLE STRANDED POLYNUCLEOTIDE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-11-23 | — | — | US | disclosed |
| WO-2023198911-A2 | NOVEL MODIFIED PROTEIN PORES AND ENZYMES | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023164676-A1 | METHODS TO GENERATE NOVEL ACYL-TRNA SPECIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-31 | — | — | WO | disclosed |
| US-11725235-B2 | Method for attaching one or more polynucleotide binding proteins to a target polynucleotide | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-08-15 | — | — | US | disclosed |
| CN-116601297-A | Modified helicase and application thereof | 北京齐碳科技有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230227799-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-07-20 | — | — | US | disclosed |
| US-20230212535-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-07-06 | — | — | US | disclosed |
| EP-4198125-A2 | PIF1-LIKE HELICASE AND USE THEREOF | Qitan Technology Ltd., Beijing (CN) | 2023-06-21 | — | — | EP | disclosed |
| US-11649480-B2 | Method for modifying a template double stranded polynucleotide | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-05-16 | — | — | US | disclosed |
| EP-4122949-A1 | MUTANT PORE | Oxford Nanopore Technologies plc (GB) | 2023-01-25 | — | — | EP | disclosed |
| EP-4108679-A1 | MODIFIED ENZYMES | Oxford Nanopore Technologies plc (GB) | 2022-12-28 | — | — | EP | disclosed |
| US-11525126-B2 | Modified helicases | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2022-12-13 | — | — | US | disclosed |
| US-11525125-B2 | Modified helicases | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2022-12-13 | — | — | US | disclosed |
| EP-4063382-A9 | PIF1-LIKE HELICASE AND APPLICATION THEREOF | Qitan Technology Ltd., Beijing (CN) | 2022-11-16 | — | — | EP | disclosed |
| EP-4063382-A1 | PIF1-LIKE HELICASE AND APPLICATION THEREOF | Qitan Technology Ltd., Beijing (CN) | 2022-09-28 | — | — | EP | disclosed |
| US-20220290223-A1 | PIF1-LIKE HELICASE AND USE THEREOF | Qitan Technology Ltd. (CN) | 2022-09-15 | — | — | US | disclosed |
| EP-3204406-B1 | MODIFIED ENZYMES | OXFORD NANOPORE TECH PLC (GB) | 2022-07-06 | — | — | EP | disclosed |
| US-20220162568-A1 | PORE | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2022-05-26 | — | — | US | disclosed |
| US-20220135956-A1 | MODIFIED ENZYMES | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2022-05-05 | — | — | US | disclosed |
| EP-3097210-B2 | METHOD FOR ATTACHING ONE OR MORE POLYNUCLEOTIDE BINDING PROTEINS TO A TARGET POLYNUCLEOTIDE | OXFORD NANOPORE TECH LTD (GB) | 2022-04-20 | — | — | EP | disclosed |
| EP-3953369-A1 | PORE | Oxford Nanopore Technologies plc (GB) | 2022-02-16 | — | — | EP | disclosed |
| US-11180741-B2 | Modified enzymes | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2021-11-23 | — | — | US | disclosed |
| CN-113677693-A | Hole(s) | 牛津纳米孔科技公司 | 2021-11-19 | — | — | CN | disclosed |
| US-20210123032-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2021-04-29 | — | — | US | disclosed |
| US-20210009971-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2021-01-14 | — | — | US | disclosed |
| EP-3464615-B1 | METHOD | OXFORD NANOPORE TECH LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| EP-3741847-A1 | MODIFIED HELICASES | Oxford Nanopore Technologies Limited (GB) | 2020-11-25 | — | — | EP | disclosed |
| US-20200360542-A1 | SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | THE JOHNS HOPKINS UNIVERSTY | 2020-11-19 | — | — | US | disclosed |
| US-20200360542-A1 | SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | THE JOHNS HOPKINS UNIVERSTY | 2020-11-19 | — | — | US | disclosed |
| US-10808231-B2 | Modified helicases | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2020-10-20 | — | — | US | disclosed |
| WO-2020208357-A1 | PORE | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2020-10-15 | — | — | WO | disclosed |
| CN-111534504-A | Methods of linking one or more polynucleotide binding proteins to a target polynucleotide | 牛津纳米孔技术公司 | 2020-08-14 | — | — | CN | disclosed |
| US-10736974-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-10736974-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-10724018-B2 | Modified helicases | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2020-07-28 | — | — | US | disclosed |
| US-20200087724-A1 | METHOD FOR ATTACHING ONE OR MORE POLYNUCLEOTIDE BINDING PROTEINS TO A TARGET POLYNUCLEOTIDE | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2020-03-19 | — | — | US | disclosed |
| CN-106103741-B | Methods of linking one or more polynucleotide binding proteins to a target polynucleotide | 牛津纳米孔技术公司 | 2020-03-13 | — | — | CN | disclosed |
| EP-3575410-A2 | MODIFIED ENZYMES | Oxford Nanopore Technologies Limited (GB) | 2019-12-04 | — | — | EP | disclosed |
| US-10385389-B2 | Method for attaching one or more polynucleotide binding proteins to a target polynucleotide | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20190194722-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2019-06-27 | — | — | US | disclosed |
| EP-3464615-A1 | METHOD | Oxford Nanopore Technologies Limited (GB) | 2019-04-10 | — | — | EP | disclosed |
| EP-3440098-A1 | MUTANT PORE | Oxford Nanopore Technologies Limited (GB) | 2019-02-13 | — | — | EP | disclosed |
| EP-3097210-B1 | METHOD FOR ATTACHING ONE OR MORE POLYNUCLEOTIDE BINDING PROTEINS TO A TARGET POLYNUCLEOTIDE | OXFORD NANOPORE TECH LTD (GB) | 2018-11-14 | — | — | EP | disclosed |
| US-20180037874-A9 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2018-02-08 | — | — | US | disclosed |
| WO-2017203267-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2017-11-30 | — | — | WO | disclosed |
| US-20170333576-A1 | NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170333576-A1 | NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-11-23 | — | — | US | disclosed |
| WO-2017174990-A1 | MUTANT PORE | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
| EP-3204406-A2 | MODIFIED ENZYMES | Oxford Nanopore Technologies Limited (GB) | 2017-08-16 | — | — | EP | disclosed |
| US-20170107569-A1 | METHOD FOR ATTACHING ONE OR MORE POLYNUCLEOTIDE BINDING PROTEINS TO A TARGET POLYNUCLEOTIDE | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2017-04-20 | — | — | US | disclosed |
| EP-3097210-A1 | METHOD FOR ATTACHING ONE OR MORE POLYNUCLEOTIDE BINDING PROTEINS TO A TARGET POLYNUCLEOTIDE | Oxford Nanopore Technologies Limited (GB) | 2016-11-30 | — | — | EP | disclosed |
| US-20160257942-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2016-09-08 | — | — | US | disclosed |
| EP-3058088-A2 | MODIFIED ENZYMES | Oxford Nanopore Technologies Limited (GB) | 2016-08-24 | — | — | EP | disclosed |
| WO-2016055777-A2 | MODIFIED ENZYMES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2016-04-14 | — | — | WO | disclosed |
| WO-2015110813-A1 | METHOD FOR ATTACHING ONE OR MORE POLYNUCLEOTIDE BINDING PROTEINS TO A TARGET POLYNUCLEOTIDE | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2015-07-30 | — | — | WO | disclosed |
| US-20150191709-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2015-07-09 | — | — | US | disclosed |
| WO-2015055981-A2 | MODIFIED ENZYMES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2015-04-23 | — | — | WO | disclosed |
| US-6737416-B2 | THROMBOLYTIC AGENT HAVING HIGHER SAFETY | MEIJI SEIKA KAISHA LTD. (JP) | 2004-05-18 | — | — | US | disclosed |
| US-20030119787-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | MEIJI SEIKA KAISHA LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
| US-6576627-B1 | Such as 7-amino-2-((2-methyl-1-(3-phenylpropanoylamino)-propyl)hydroxyphosphinoyl) -methylheptanoic acid; thrombotic disease | MEIJI SEIKA KAISHA LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
| EP-1152004-B1 | Phosphonic acid derivatives having carboxypeptidase B inhibitory action | MEIJI SEIKA KAISHA (JP) | 2003-05-07 | — | — | EP | disclosed |
| EP-1174434-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | MEIJI SEIKA KAISHA LTD. (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1152004-A1 | PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITORY ACTIVITY | MEIJI SEIKA KAISHA LTD. (JP) | 2001-11-07 | — | — | EP | disclosed |
| US-4900860-A | Process for preparing phosphonyloxyacyl amino acids | E. R. SQUIBB & SONS, INC. (US) | 1990-02-13 | — | — | US | disclosed |
| US-4885380-A | REACTING PHOSPHONIC ACID DICHLORIDE WITH ALPHA-HYDROXY ACID TO FORM CYCLIC MIXED ANHYDRIDE; REACTING WITH AMINO ACID | THOTTATHIL JOHN K (US) | 1989-12-05 | — | — | US | disclosed |
| US-4885380-A | REACTING PHOSPHONIC ACID DICHLORIDE WITH ALPHA-HYDROXY ACID TO FORM CYCLIC MIXED ANHYDRIDE; REACTING WITH AMINO ACID | THOTTATHIL JOHN K (US) | 1989-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119787-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | CPB1, RNPEP, CPN1 | MEN1 3845/4885KMT2A 2641/4885GAA 180/4885 |
| US-20200360542-A1 | SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | FOLH1, PSMA3, PSMA7 | MEN1 844/4885KMT2A 3647/4885GAA 402/4885 |
| US-11525126-B2 | Modified helicases | DDX21, DDX5, DDX17 | MEN1 2969/4885KMT2A 2941/4885GAA 2839/4885 |
| US-11911488-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | FOLH1, PSMA3, PSMA7 | MEN1 844/4885KMT2A 3647/4885GAA 402/4885 |
| US-20240417704-A1 | MODIFIED HELICASES | DDX21, DDX5, DDX17 | MEN1 2969/4885KMT2A 2941/4885GAA 2839/4885 |
| US-10808231-B2 | Modified helicases | DDX21, DDX5, DDX17 | MEN1 2969/4885KMT2A 2941/4885GAA 2839/4885 |
| US-20210123032-A1 | MODIFIED HELICASES | DDX21, DDX5, DDX17 | MEN1 2969/4885KMT2A 2941/4885GAA 2839/4885 |
| US-12252717-B2 | Modified helicases | DDX21, DDX5, DDX17 | MEN1 2969/4885KMT2A 2941/4885GAA 2839/4885 |
| US-20170333576-A1 | NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | FOLH1, PSMA3, PSMA7 | MEN1 1001/4885KMT2A 3946/4885GAA 605/4885 |
| US-10736974-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | FOLH1, PSMA3, PSMA7 | MEN1 844/4885KMT2A 3647/4885GAA 402/4885 |
| US-20230227799-A1 | MODIFIED HELICASES | DDX21, DDX5, DDX17 | MEN1 2969/4885KMT2A 2941/4885GAA 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.